- Report
- April 2023
- 117 Pages
Global
From €4184EUR$4,750USD£3,677GBP
- Report
- February 2024
- 79 Pages
North America
From €3039EUR$3,450USD£2,671GBP
- Report
- September 2023
- 173 Pages
Global
From €3919EUR$4,450USD£3,445GBP
- Report
- November 2023
- 87 Pages
North America
From €3039EUR$3,450USD£2,671GBP
- Report
- October 2023
- 180 Pages
Global
From €1101EUR$1,250USD£968GBP
€2202EUR$2,500USD£1,935GBP
- Report
- June 2025
- 109 Pages
Colombia
From €3170EUR$3,599USD£2,786GBP
- Report
- February 2024
- 110 Pages
North America
From €1321EUR$1,500USD£1,161GBP

Strabismus, also known as crossed eyes, is a condition in which the eyes do not align properly. It is a common condition in children, but can also occur in adults. It is usually treated with corrective lenses, such as glasses or contact lenses, or with surgery. In the optical market, strabismus is a major area of focus, as it affects a large portion of the population. Companies in the optical market are developing new technologies to diagnose and treat strabismus, such as computerized eye tracking systems and advanced imaging techniques. Additionally, companies are researching new treatments, such as botulinum toxin injections, to reduce the symptoms of strabismus.
Some companies in the strabismus market include Johnson & Johnson Vision Care, Inc., Bausch + Lomb, CooperVision, Inc., Essilor International, and Hoya Corporation. Show Less Read more